FDA records identify Wellysis Corp. at an address in Seoul, Republic of Korea, with Young Juhn listed as contact and CEO. The K254255 record shows S-Patch CardioAI received on December 29, 2025, and decided on September 25, 2026, with decision code SESE, described as substantially equivalent. The same record lists the advisory committee as Cardiovascular and the clearance type as Traditional, with a summary statement. Wellysis’ own announcement, dated October 8, 2026, describes the clearance as covering AI-powered ECG analysis software and frames it as adding analysis to the S-Patch ECG monitoring solution. [1][2][4]
The K254255 filing and its scope
The FDA 510(k) database entry for K254255 names Wellysis Corp. as applicant and S-Patch CardioAI as the device, with product code DQK and a decision date of September 25, 2026. The accompanying FDA letter of the same date lists regulation number 21 CFR 870.1425, regulation name Programmable Diagnostic Computer, regulatory class Class II, and product codes DQK and DPS. The letter is addressed to Young Juhn as CEO at the Seoul address. [1][2]
The K254255 summary compares S-Patch CardioAI with DeepRhythmAI (K210822) across analysis outputs, listing QRS, heart rate determination and R-R interval measurement as present in both. The same comparison table records two-lead ECG for S-Patch CardioAI against single-lead ECG for the predicate, and states that neither device has a primary display or graphical user interface. [2]
S-Patch CardioAI as described by the manufacturer
Wellysis’ product page describes S-Patch CardioAI as AI algorithms for ECG analysis, built on deep neural network technology trained on a database of continuous ECG recordings across patient demographics and conditions. The page states that the algorithms are used commercially for cardiac monitoring and arrhythmia detection and that the product is used in more than 15 countries across the Americas, Europe, Asia and Oceania. These are manufacturer statements rather than FDA findings. [7]
The company’s October 8, 2026 announcement states that the clearance adds FDA-cleared AI analysis to the S-Patch ECG monitoring solution, extending it beyond ECG acquisition, and that analysis of S-Patch ECG data can be integrated into third-party ECG platforms and existing clinical workflows. The announcement also describes the software as intended to automate analysis and support interpretation by healthcare professionals. [4]
The wider S-Patch system in company documentation
A Wellysis brochure describes S-Patch as a lightweight patch-type wearable for continuous ECG monitoring and analysis, and states that it launched in more than 16 countries, was deployed to more than 600 hospitals and clinics, received FDA 510(k) clearance, and holds CE, ISO 13485, MFDS and GMP certifications. Those figures and certifications come from the brochure and are not confirmed in the FDA records reviewed here. [5]
Wellysis’ website presents the S-Patch workflow as four stages: a wearable patch for biosignal collection, a mobile app for managing and monitoring a test, a web reading and service layer for data analysis, and a final PDF ECG report. The site states that S-Patch is powered by a Samsung Smart Health Processor. [6]
What the records establish and what they do not
As of November 20, 2026, the linked FDA collection contains one record, a 510(k) with decision SESE, and the record sample contains that same single entry, K254255. These counts describe the linked filings at that date and are not measures of total company sales, total portfolio or safety performance. No recall records appear in the linked collection. [1]
The FDA records identify Wellysis Corp. as the legal applicant for K254255 and give a Seoul address for correspondence; that filing address is not evidence of a corporate headquarters. Wellysis’ published contact information lists a Seoul headquarter address for Wellysis Corp. and a Houston office for Wellysis USA, Inc., with Young Juhn as CEO. No parent, ownership structure or brand relationship beyond those named entities is verified in the reviewed records. [1][4][6]

